{"url":"https://lda.senate.gov/api/v1/filings/420936dd-a592-4347-93a7-e1dd14d4e7d4/","filing_uuid":"420936dd-a592-4347-93a7-e1dd14d4e7d4","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2025,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/420936dd-a592-4347-93a7-e1dd14d4e7d4/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"John McManus","dt_posted":"2026-01-20T18:12:30-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"610 10th St. NW","registrant_address_2":"Suite 300","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":286096,"url":"https://lda.senate.gov/api/v1/registrants/286096/","house_registrant_id":36969,"name":"THE MCMANUS GROUP","description":"Consulting","address_1":"610 10th St. NW","address_2":"Suite 300","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JORDAN OPDAHL","contact_telephone":"+1 301-775-7048","dt_updated":"2026-07-20T15:27:02.288049-04:00"},"client":{"id":64414,"url":"https://lda.senate.gov/api/v1/clients/64414/","client_id":64414,"name":"BIOWOUND SOLUTIONS","general_description":"Biologics Company","client_government_entity":null,"client_self_select":false,"state":"NV","state_display":"Nevada","country":"US","country_display":"United States of America","ppb_state":"NV","ppb_state_display":"Nevada","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-02-20"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":9573,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MCMANUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140472,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"WHALEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}